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Abstract
Background: N-acetylcysteine (NAC) or sodium bicarbonate (NaHCO3), singly or combined, inconsistently prevent patients
exposed to radiographic contrast media from developing contrast-induced acute kidney injury (CI-AKI).
Objective: We asked whether intravenous isotonic saline and either NaHCO3 in 5% dextrose or else a high dose of NAC in
5% dextrose prevent CI-AKI in outpatients exposed to high-osmolal iodinated contrast medium more than does saline
alone.
Methods: This completed prospective, parallel, superiority, open-label, controlled, computer-randomized, single-center,
Brazilian trial (NCT01612013) hydrated 500 adult outpatients (214 at high risk of developing CI-AKI) exposed to ioxitalamate
during elective coronary angiography and ventriculography. From 1 hour before through 6 hours after exposure, 126
patients (group 1) received a high dose of NAC and saline, 125 (group 2) received NaHCO3 and saline, 124 (group 3) received
both treatments, and 125 (group 4) received only saline.
Results: Groups were similar with respect to age, gender, weight, pre-existing renal dysfunction, hypertension, medication,
and baseline serum creatinine and serum cystatin C, but diabetes mellitus was significantly less prevalent in group 1. CI-AKI
incidence 72 hours after exposure to contrast medium was 51.4% (257/500), measured as serum creatinine . (baseline+
0.3 mg/dL) and/or serum cystatin C . (1.1? baseline), and 7.6% (38/500), measured as both serum creatinine and serum
cystatin C . (baseline+0.3 mg/dL) or . (1.25 ? baseline). CI-AKI incidence measured less sensitively was similar among
groups. Measured more sensitively, incidence in group 1 was significantly (p,0.05) lower than in groups 2 and 3 but not
group 4; adjustment for confounding by infused volume equalized incidence in groups 1 and 3.
Conclusion:: We found no evidence that intravenous isotonic saline and either NaHCO3 or else a high dose of NAC prevent
CI-AKI in outpatients exposed to high osmolal iodinated contrast medium more than does saline alone.
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Introduction
Radiographic contrast media administered intravenously induce
acute kidney injury (CI-AKI). Patients with CI-AKI experience an
increase in the risk of mortality and in the cost and duration of
hospitalization [1–5]. Despite advances in understanding the
physiopathology of CI-AKI, the incidence of CI-AKI worldwide is
significant and increasing because the use of contrast media is
increasing [6]. For example, contrast media was used in an
estimated 1 million percutaneous coronary interventions in the
United States in 2010 [7]. Modern radiology units have
abandoned the use of high-osmolal contrast media in patients
with chronic kidney disease because the associated risk of inducing
CI-AKI is high. But for economic reasons and because it is not
clear whether the risk of developing CI-AKI is clinically important
for the general population of patients, many public hospitals in
Brazil and worldwide continue to use such media.
Contrast media is thought to induce the CI-AKI syndrome
through a variety of mechanisms, including those that form and
concentrate toxins–free radicals and acidity–in renal tubules
[1,8,9]. Yet most clinical trials of the effect of renal detoxicants
on CI-AKI incidence have tested only small homogeneous samples
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of patients, at high risk of developing CI-AKI due to affliction by
diabetes mellitus or renal dysfunction, who were exposed to low-
or iso-osmolal contrast media. In these patients, intravenous
hydration with isotonic saline decreased the incidence of CI-AKI
reliably, but hydration supplemented with the detoxicants N-
acetylcysteine (NAC) or sodium bicarbonate (NaHCO3) further
decreased incidence only inconsistently [10–17].
We hypothesized that CI-AKI-inducing mechanisms responsive
to NAC or NaHCO3 treatment would be more evident in a large
heterogeneous sample of outpatients exposed to high-osmolal
contrast media. Our objective was to determine whether
intravenously hydrating outpatients with isotonic saline supple-
mented with NaHCO3 or a high dose of NAC would protect them
from developing CI-AKI within 72 hours after exposure to high-
osmolal contrast medium more than would hydrating them with
saline alone. We describe a completed single-center randomized
controlled trial of 500 outpatients exposed to the high-osmolal
contrast agent ioxitalamate during elective coronary angiography
or ventriculography in which we compared the efficacy of four
treatment strategies for preventing CI-AKI.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Population and Study Protocol
We conducted this prospective, open-label, randomized, paral-
lel-assignment, active-comparator, superiority, controlled trial
(registered as NCT01612013 at ClinicalTrials.gov, http://
clinicaltrials.gov/ct2/show/study/NCT01612013) at a single hos-
pital center in Brazil between January 2007 and May 2009 in
accordance with the principles of good clinical practice and the
Declaration of Helsinki. The Research and Ethics Committee of
Catholic University of Brasilia approved of the study protocol and
all patients included in this trial gave informed written consent.
All outpatients 18 years of age and older scheduled for elective
coronary angiography or ventriculography were eligible for
inclusion in this study. A nurse, blinded to the trial hypothesis
and from whom the random sequence of allocation to treatment
was concealed, enrolled 500 eligible outpatients, excluding those
who: were less than 18 years of age, received an iodinated contrast
medium intravascularly within 30 days before evaluation for
inclusion, received emergency coronary catheterization, experi-
enced pulmonary edema or acutely decompensated congestive
heart failure, were using nonsteroidal anti-inflammatory drugs or
metformin at the time of the study, or declined to participate in the
trial. No patient received theophylline, dopamine, or mannitol
during the study.
A second nurse, blinded to the trial hypothesis and from whom
enrollment information was concealed, in a room apart from that
used for enrollment, prepared the medications and randomly
allocated by computer without restriction each of 500 hundred
outpatients satisfying the inclusion/exclusion criteria of this trial to
one of four parallel treatment groups: NAC plus saline (group 1,
n = 126), NaHCO3 plus saline (group 2, n = 125), NAC and
NaHCO3 plus saline (group 3, n = 124), or saline (standard of care
control group 4, n = 125).
Coronary angiography and ventriculography were performed
according to standard protocols. Upon enrollment, all patients
were instructed to avoid use of diuretic drugs for 48 hours before
and after these procedures. All patients received the ionic, high-
osmolality (2130 mOsm/kg, viscosity 7.5 mPaNs) contrast agent
ioxitalamate (350 mg/mL iodine, Telebrix 35, Guerbet, Brazil).
The dose of contrast medium administered, clinical management
of the patient, and all adjunctive drug therapies were left to the
discretion of the attending cardiologist.
Figure 1. Flow of 500 outpatients through a parallel trial of four treatments for preventing CI-AKI. Practice of the trial design.
Abbreviations: CI-AKI (contrast-induced acute kidney injury), IV (intravenous), NAC (N-acetylcysteine), NaHCO3 (sodium bicarbonate).
doi:10.1371/journal.pone.0107602.g001
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Medications
Patients received medications intravenously 60 minutes imme-
diately before, during, and 6 hours immediately after contrast
medium was administered. NAC (Flucistein, 100 mg/mL, Neo
Quı´mica, Brazil) in 500 mL of 5% dextrose was given in bolus at
150 mg/(kgNh) before contrast medium was administered, then at
50 mg/(kgNh). NaHCO3, prepared by mixing 150 mEq (15
ampoules) of sodium bicarbonate (8.4%, Equiplex, Brazil) with
1 L of 5% dextrose, was given in bolus at 3.5 mL/(kgNh) before
contrast medium was administered, then at 1.18 mL/(kgNh). Saline
(0.9%, isotonic) was given intravenously at 1 mL/(kgNh).
Creatinine and Cystatin C Measurements
Blood samples were obtained at baseline (before medication and
contrast medium were infused and one hour before angiography
or ventriculography) and at 24, 48, and 72 hours after contrast
medium was administered.
Serum levels of creatinine (sCr) measured by the colorimetric
method of Jaffe [18], and of cystatin C (sCys C) measured by an
immunonephelometric method (Dade Behring, Marburg, Germany
[19]), were used as biomarkers of the decreased renal glomerular
filtration associated with CI-AKI. We estimated glomerular filtration
rates (eGFR) in two ways: 1) eGFR MDRDð Þ~186:
sCrð Þ{1:154: ageð Þ{0:203: 0:742ifFemaleð Þ, using sCr as a biomarker
and the 4-variable Modification of Diet in Renal Disease formula
(eGFR MDRD) as a model [20], and 2) eGFR sCys{Cð Þ~127:7:
sCys{Cð Þ{1:17: ageð Þ{0:13: 0:91ifFemaleð Þ, using sCys C as a
biomarker [21].
End Points and Definitions
The primary end point of this study was the development of CI-AKI
between baseline and 72 hours after administration of contrast
medium. Because the diagnostic definition of CI-AKI is evolving
[22,23], this study used two definitions of CI-AKI: 1) more sensitively,
as sCr§ baselinez0:3 mg=dLð Þ and/or both sCr and sCys{
C§ 1:1:baselineð Þ; and 2) less sensitively, as both sCr and sCys{
C§ baselinez0:3 mg=dLð Þ or § 1:25:baselineð Þ. The secondary
end point was the development of CI-AKI in a subgroup of high-risk
patients with diabetes or pre-existing renal dysfunction, defined as a
calculated baseline creatinine clearance ,60 ml/min/1.73 m2 indic-
ative of chronic kidney disease [1].
Statistical Analysis
Values of continuous variables were summarized as mean
(standard deviation). Values of categorical variables were summa-
rized as frequency (percentage). P-values ,0.05 were considered
statistically significant.
A two-sided chi-square test (x2 = 10.9050, df = 3) indicated that
a sample size of 500 patients (125 patients per group) would have
80% power at a type I error probability of 0.05 to detect a
statistically significant difference among the four groups and to
detect a clinically meaningful 75% reduction of CI-AKI in
treatment group 3. For this power calculation, the incidence of CI-
AKI in control group 4 was estimated to be 15% because high-
osmolal contrast medium was used in this study [1].
Homogeneity of the groups at baseline was evaluated with a chi
square test for categorical variables (gender, diabetes mellitus,
hypertension, medications, and pre-existing renal dysfunction) and
with ANOVA for continuous variables (age, diastolic and systolic
blood pressure, volume of contrast medium, infused volume,
weight, serum creatinine, serum cystatin C, eGFR (MDRD), and
eGFR (sCys C)). Multiple logistic regression analysis was used
without covariables to compare the incidence of CI-AKI among
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the 4 groups and used with covariables (diabetes and infused
volume; or the set of diabetes, infused volume, gender, age, and
weight) to estimate a potential confounding effect of these
covariables. A difference .10% in odds ratios calculated with
and without a covariable was considered to indicate a confounding
effect of the covariable.
To compensate for incomplete cases that were missing data,
SAS software 9.3 was used to perform 4 multiple imputations,
assuming that the data were missing at random, to achieve a
relative imputation efficiency of at least 95%. For each variable
and patient, each combined data point estimate from the 4
multiple imputations was calculated as the average of the 4
resulting complete-data estimates (Table S1).
Both an intent-to-treat analysis (n = 500) using imputed data
and a per-protocol analysis (n = 425) using only the data of
complete cases were performed using the software SPSS 15.0
(SPSS Corp., Chicago, Illinois, USA) for Windows.
The authors had full access to, and took full responsibility for
the integrity of, the data. All authors have read and agreed with
the manuscript as written.
Results
Patient Population and Baseline Characteristics
Of the 500 outpatients randomized to 4 treatment groups and
exposed to contrast medium, 15% (75 of 500) were missing both
sCr and sCys C data for some time points and 0.4% (2 of 500)
were missing all sCr data (baseline, 24, 48 and 72 hours; Figure 1).
The proportions of missing data were equivalent among all 4
groups, with no evidence of differential loss according to assigned
treatment. Data was imputed to compensate for incomplete cases
(Table S1).
Baseline values of patient traits in the 4 groups were well
matched, except the prevalence of diabetes mellitus was signif-
icantly lower in group 1 than in groups 2 and 3 but not group 4
(Tables 1, S2, S3). Half of the patients were at high risk for
developing CI-AKI, including 42.8% (214 of 500) who had pre-
existing diabetes or renal dysfunction and an additional 7.2% (36
of 500) who received a large volume (more than 140 mL) of
contrast medium.
Incidence of CI-AKI
As expected [22], the observed incidence of CI-AKI depended
on how CI-AKI was defined. Incidence among patients in the
intent-to-treat sample was 51.4% (257 of 500) under the more
sensitive definition of CI-AKI, but only 7.6% (38/500) under the
less sensitive definition (Table 2). Average levels of sCr used to
indicate CI-AKI were lowest at baseline and highest at 24 hours
after exposure to contrast medium for groups 1 and 4 and at 48
hours for groups 2 and 3 (Figure 2, panel A). Average levels of
sCys C used to indicate CI-AKI were lowest at baseline for groups
2, 3, and 4 and at 48 hours 4 for group 1; average levels were
highest at baseline for group 1, at 24 hours for group 2, at 48 hours
for group 3, and at 72 hours for group 4 (Figure 2, panel B).
Under the less sensitive definition of CI-AKI, the incidence of
CI-AKI among the four treatment groups in the intent-to-treat
Figure 2. Change in serum creatinine and cystatin C levels of 500 outpatients exposed to ioxitalamate. Mean of serum creatinine (panel
A) and serum cystatin C (panel B) concentrations before (baseline) and after administration of ioxitalamate, according to treatment group.
Treatments: NAC (N-acetylcysteine plus saline; group 1), NaHCO3 (sodium bicarbonate plus saline; group 2), NAC+NaHCO3 (N-acetylcysteine plus
sodium bicarbonate plus saline; group 3), saline (group 4). Means among the treatment groups did not differ significantly. Error bars indicate 1
standard deviation about the mean.
doi:10.1371/journal.pone.0107602.g002
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sample was uniform; but under the more sensitive definition, the
incidence was significantly lower in group 1 than in groups 2 and 3
but not group 4 (Table 2). Of the conditions tested (age, diabetes,
gender, infused volume, and weight), only the effect of infused
volume appeared to be confounded with the effect of treatment
(Table 3). Adjusting for that confounding effect equalized the
Table 3. Multiple logistic regression analysis of potential confounding.
Sample Modela Predictorb
Odds
Ratio
Confidence Interval
(95%) P-valuec
Difference in Odds
Ratios (%)d
Total 1
(unadjusted)
NAC
(reference)
– – – –
NaHCO3 2.36 1.42; 3.91 0.001 –
NAC + NaHCO3 2.18 1.31; 3.61 0.003 –
Saline only 1.5 0.91; 2.47 0.114 –
2 (adjusted only for
infused volume)
NAC
(reference)
– – – –
NaHCO3 2.33 1.4; 3.87 0.001 1.27
NAC + NaHCO3 0.97 0.19; 4.99 0.97 55.5
Saline only 3.34 0.65; 17.05 0.147 -122.67
Infused
volume
1 1; 1 0.31 –
3 (adjusted for three
predictors)
NAC (reference) – – – –
NaHCO3 2.36 1.36; 4.1 0.002 0
NAC + NaHCO3 1.39 0.18; 10.86 0.752 36.24
Saline only 1.65 0.2; 13.26 0.64 -10
Infused
volume
1 1; 1 0.789 –
Diabetes mellitus 1.17 0.73; 1.9 0.511 –
Renal disease 1.02 0.65; 1.61 0.918 –
High Riske 4 (unadjusted) NAC (reference) – – – –
NaHCO3 0.66 0.28; 1.53 0.329 –
NAC + NaHCO3 1.49 0.69; 3.23 0.307 –
Saline only 1.01 0.45; 2.27 0.976 –
5 (adjusted only for
infused volume)
NAC
(reference)
– – – –
NaHCO3 1.5 0.08; 28.22 0.786 -127.27
NAC + NaHCO3 3.51 0.17; 70.99 0.414 -135.57
Saline only 5.27 0.02; 1537.05 0.566 -421.78
Infused
volume
1 1; 1 0.565 –
6 (adjusted for three
predictors)
NAC (reference) – – – –
NaHCO3 2.23 0.88; 5.61 0.09 -237.88
NAC + NaHCO3 1.16 0.05; 25.99 0.924 22.15
Saline only 1.35 0.06; 31.48 0.851 -33.66
Infused volume 1 1; 1 0.98 –
Diabetes mellitus 1.72 0.7; 4.22 0.239 –
Renal disease 1.54 0.61; 3.92 0.364 –
Adjustment for potential confounding of the effect of infused volume and of baseline diabetes and renal disease on induction of CI-AKI by ioxitalamate in the intent-to-
treat (n = 500) and high risk (n = 250) samples. sCr (serum creatinine mg/dL); sCys C (serum cystatin C; mg/dL). Definition of CI-AKI (contrast-induced acute kidney injury):
sCr$(baseline+0.3 mg/dL) and/or both sCr and sCys C$(baseline ? (1+10%)).
aRegression models adjusted or unadjusted for potential confounding by infused volume and by baseline diabetes and renal disease.
bPredictor (all treatments included saline): NAC (N-acetylcysteine), NaHCO3 (sodium bicarbonate), saline alone; infused volume (total volume of oxitalamate plus
treatment administered intravenously).
cbolded 2-tailed P-values were considered statistically significant and refer to the null hypothesis that the odds ratio = 1.
dDifference in odds ratios (%) = (100 ? ((Unadjusted odds ratio) – (Adjusted odds ratio))/(Unadjusted odds ratio)); a difference of at least 10% (bolded value) was
considered evidence of confounding.
ePatients at high risk of developing CI-AKI due to affliction with diabetes mellitus or renal dysfunction at baseline or due to receiving .140 mL of ioxitalamate.
doi:10.1371/journal.pone.0107602.t003
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effect of treatment in groups 1 and 3 but left the difference
between groups 1 and 2 unchanged. We found no evidence that
diabetic patients with pre-existing renal dysfunction were at
increased risk of developing CI-AKI (Table 3).
Adverse events
No patient developed renal failure requiring temporary dialysis.
No patient was withdrawn from the study, although adverse events
occurred in 5 patients treated with NAC (rash, nausea, headache,
and bronchospasm) and in 4 patients treated with NaHCO3
(pulmonary edema).
Similar results were obtained with a per-protocol analysis.
Discussion
The main finding of this trial, like that of some [24–33] trials, is
that isotonic saline supplemented with NAC or NaHCO3 provides
outpatients exposed to contrast medium no more protection from
developing CI-AKI than does isotonic saline alone. But the lower
incidence of CI-AKI (defined more sensitively) in group 1 than in
group 2 suggests that a larger trial of outpatients might detect a
small but clinically meaningful benefit of NAC treatment,
consistent with the finding of other trials [34–41]. Preclinical
studies suggest that saline hydration, NAC, and NaHCO3 may
protect against the damaging effects of contrast media by
inhibiting the formation, accumulation, or concentration of free
radicals responsible for oxidative damage to renal tubules
[22,42,43].
We observed a higher incidence of CI-AKI than have others
[1,22,23], which might be explained in three ways. 1) Specialized
diagnostic definitions of CI-AKI–for example, one for patients
with diseased kidneys and another for patients with healthy
kidneys–may be needed for consistency among trials. The
definition of CI-AKI as an increase in sCr [44] or sCys C [45]
above baseline was developed in trials of patients with diseased
kidneys [22]. If that definition is less specific for patients with
healthy kidneys, then using it may overestimate the incidence of
CI-AKI in trials such as ours that include a large proportion of
such patients. 2) A more reliable biomarker may be needed. A
transient increase of popular biomarkers to levels indicating CI-
AKI can result from conditions unrelated to CI-AKI: transient
hypotension or variations in dietary intake and hydration affect
sCr levels [22,46,47] and thyroid dysfunction affects sCys C levels
[48,49]. If those conditions were more pervasive in our single-
center trial than in other trials, then our choice of biomarkers
would have led us to overestimate the incidence of CI-AKI. 3) Our
observations suggest that high-osmolal contrast medium may be
toxic to all patients. Unlike most trials, which expose patients with
pre-existing renal dysfunction to only low- or iso-osmolal contrast
medium, our trial exposed all patients to high-osmolal contrast
medium [22]. We observed both: an equal incidence of CI-AKI in
low-risk diabetic patients without pre-existing renal dysfunction
and in high-risk diabetic patients with pre-existing renal dysfunc-
tion; and an overall incidence (51.4%, 257/500) that exceeded the
percentage of patients at high risk for developing CI-AKI (50%,
250/500). We therefore recommend abandoning the use of high-
osmolal contrast media worldwide.
Limitations
The results of this study should not be generalized to patients,
such as those with chronic kidney disease, who are exposed to
hypo- or iso-osmolal contrast media. High-osmolal contrast media
are more nephrotoxic to patients with pre-existing renal failure
than are low- or iso-osmolal media [50,51]. All outpatients in our
trial were recruited from one hospital and received only high-
osmolal contrast medium. Half of them had normal kidney
function and were not at high risk for developing CI-AKI.
Optimal methods of administering medication to treat CI-AKI
have not yet been identified. Total infused volume appeared to be
a confounding factor in our study. And although the Kidney
Disease Improving Global Outcomes and European Renal Best
Practice guideline recommends oral administration of NAC to
patients at risk of developing CI-AKI [52], recent findings suggest
that orally administered NAC provides no therapeutic benefit [53–
56].
We hypothesized that a large trial of diverse outpatients might
detect mechanisms of CI-AKI development that would respond to
NAC or NaHCO3 treatments. Even though this trial failed to
detect such mechanisms, our hypothesis might still be useful. Our
trial was underpowered due to a flaw in our calculation of
statistical power. Rather than assume a large effect of treatment (a
75% decrease in the incidence of CI-AKI), we should have
assumed a smaller effect no greater than 40% [39,57,58]. A post
hoc analysis showed that, under the more sensitive definition of
CI-AKI for a sample size of 500 patients and a 5% level of
significance, the power to detect a statistically significant difference
from the control group 4 was 27% (group 2), 21% (group 1), and
18% (group 3); under the less sensitive definition of CI-AKI, the
power was 21% (group 2), 10% (group 1), and 14% (group 3).
This trial, like most others, suffered from loss to follow up.
Everyone agrees that missing data should be minimized because it
precludes the use of standard statistical techniques for intent-to-
treat analysis and because per-protocol analysis can substantially
bias estimates of treatment effects in superiority trials [59–61] like
ours. But not everyone agrees on how to address missing data. The
statistical technique of multiple imputation (MI) that we used to
compensate for missing data in this study is widely accepted and
usually allows analysis of data from all patients randomized to
treatment without introducing bias [62–64].
We were unable to distinguish variations in sCr and sCys C
associated with exposure to ioxitalamate from variations not
associated with exposure [22,46,65] because our trial lacked a
placebo control group that was not exposed to ioxitalamate.
Conclusion
Analysis of the results of this prospective, randomized, single-
center, controlled trial revealed no evidence that intravenously
hydrating outpatients with isotonic saline supplemented with
NaHCO3 or a high dose of NAC protected them from developing
CI-AKI within 72 hours after exposure to high-osmolal contrast
medium more than did hydrating them with saline alone.
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